[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335157-105":59,"doc-detail-335157-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cancer-associated-mutations-in-protein-kinase-c-theta-are-loss-of-function","Cancer-associated mutations in protein kinase C theta are loss-of-function","","Cancer-associated mutations in protein kinase C theta (PKCθ) are investigated for their impact on cellular activity and protein stability. The study focuses on four mutations located in distinct regulatory regions: the autoinhibitory pseudosubstrate (R145H/C), the regulatory C1A domain (E161K), and the regulatory C-terminal tail (R635W). Live-cell CKAR2 reporter assays show that pseudosubstrate and C1A mutations impair autoinhibition, elevating basal signaling but decreasing protein stability, consistent with loss-of-function via degradation. By contrast, the C-terminal tail mutation enhances autoinhibition and stabilizes an inactive PKCθ.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cancer-associated-mutations-in-protein-kinase-c-theta-are-loss-of-function/335157/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cancer-associated-mutations-in-protein-kinase-c-theta-are-loss-of-function/335157.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which PKCθ mutations were tested and where are they located?","Question",{"text":112,"@type":113},"Four cancer-associated mutations were examined: R145H/C in the autoinhibitory pseudosubstrate, E161K in the regulatory C1A domain, and R635W in the regulatory C-terminal tail.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the pseudosubstrate and C1A domain mutations affect PKCθ activity?",{"text":117,"@type":113},"They impaired autoinhibition, leading to increased basal signaling as measured by CKAR2 in live-cell imaging.",{"name":119,"@type":110,"acceptedAnswer":120},"Why are some mutations considered loss-of-function despite increasing basal signaling?",{"text":121,"@type":113},"Impaired autoinhibition reduced PKCθ stability, so the mutant protein is degraded, resulting in functional loss. The C-terminal tail mutation behaved differently by enhancing autoinhibition and stability.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335157,1790735933,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Biochemical Journal (2024) 481 759–775 [https://doi.org/10.1042/BCJ20240148](https://doi.org/10.1042/BCJ20240148)  \nResearch Article  \nCancer-associated mutations in protein kinase C theta are loss-of-function  \nStefanie J. Hodapp1,2, Nathan Gravel3, Natarajan Kannan3 and Alexandra C. Newton1  \n1Department of Pharmacology, University of California, San Diego, La Jolla, CA 92093, U.S.A. ; 2Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, CA 92093, U.S.A. ; 3Department of Biochemistry and Molecular Biology and Institute of Bioinformatics, University of Georgia, Athens, GA 30602, U.S.A.  \nCorrespondence: Alexandra C. Newton ([anewton@health.ucsd.edu](anewton@health.ucsd.edu))  \nReceived: 2 April 2024  \nRevised: 14 May 2024  \nAccepted: 16 May 2024  \nAccepted Manuscript online:  \n16 May 2024  \nVersion of Record published:  \n10 June 2024  \nThe Ca2+-independent, but diacylglycerol-regulated, novel protein kinase C (PKC) theta (θ) is highly expressed in hematopoietic cells where it participates in immune signaling and platelet function. Mounting evidence suggests that PKCθ may be involved in cancer, particularly blood cancers, breast cancer, and gastrointestinal stromal tumors, yet how to target this kinase (as an oncogene or as a tumor suppressor) has not been established. Here, we examine the effect of four cancer-associated mutations, R145H/C in the autoinhibitory pseudosubstrate, E161K in the regulatory C1A domain, and R635W in the regulatory C-terminal tail, on the cellular activity and stability of PKCθ . Live-cell imaging studies using the genetically-encoded ﬂuorescence resonance energy transfer-based reporter for PKC activity, C kinase activity reporter 2 (CKAR2), revealed that the pseudosubstrate and C1A domain mutations impaired autoinhibition to increase basal signaling. This impaired autoinhibition resulted in decreased stability of the protein, consistent with the well-characterized behavior of Ca2+-regulated PKC isozymes wherein mutations that impair autoinhibition are paradoxically loss-of-function because the mutant protein is degraded. In marked contrast, the C-terminal tail mutation resulted in enhanced autoinhibition and enhanced stability. Thus, the examined mutations were loss-of-function by different mechanisms: mutations that impaired autoinhibition promoted the degradation of PKC, and those that enhanced autoinhibition stabilized an inactive PKC. Supporting a general loss-of-function of PKCθ in cancer, bioinformatics analysis revealed that protein levels of PKCθ are reduced in diverse cancers, including lung, renal, head and neck, and pancreatic. Our results reveal that PKCθ function is lost in cancer.  \nIntroduction  \nThe novel protein kinase C (PKC) isozyme, PKC theta (θ), is most abundantly expressed in hematopoietic cells where it transduces signals resulting in T lymphocyte and platelet activation [1–4] . Priming of naïve T cells requires two signals, antigen engagement with the T cell receptor and CD28 co-stimulation [5,6] . This event triggers the translocation of PKCθ to the immunological synapse where it forms a complex with CD28 [7–9] . This interaction is essential for proper CD28 signaling, leading to activation of transcription factors, AP-1, NFAT, and NF-κB, and ultimately T cell activation [10–14] . Although PKCθ signaling has been almost exclusively studied in immune signaling, increasing evidence suggests that PKCθ may be involved in cancer where its expression is consistently reduced compared with healthy tissue [15] . More than 200 unique cancer-associated somatic mutations have been identiﬁed in PKCθ across a variety of cancer types, raising the question of their functional relevance. Additionally, analysis of these mutations could provide insight into whether loss or gain of PKCθ function is associated with cancer, in turn informing on whether to target this highly druggable kinase as an oncogene or as a tumor suppressor.  \nPKC is a family of serine/thre","cbCaipyJLUUf4hl8","https://ap.wps.com/l/cbCaipyJLUUf4hl8","pdf",2900616,17,"English","# Introduction\n## PKCθ expression and immune signaling\n## Cancer relevance and functional uncertainty\n## PKC family regulation overview","[{\"question\":\"Which PKCθ mutations were tested and where are they located?\",\"answer\":\"Four cancer-associated mutations were examined: R145H/C in the autoinhibitory pseudosubstrate, E161K in the regulatory C1A domain, and R635W in the regulatory C-terminal tail.\"},{\"question\":\"How did the pseudosubstrate and C1A domain mutations affect PKCθ activity?\",\"answer\":\"They impaired autoinhibition, leading to increased basal signaling as measured by CKAR2 in live-cell imaging.\"},{\"question\":\"Why are some mutations considered loss-of-function despite increasing basal signaling?\",\"answer\":\"Impaired autoinhibition reduced PKCθ stability, so the mutant protein is degraded, resulting in functional loss. The C-terminal tail mutation behaved differently by enhancing autoinhibition and stability.\"}]","Cancer-associated mutations in protein kinase C theta are loss-of-function | PDF",1790009827,43]